Skye Bioscience Q4 net loss $9.7M; Phase 2a obesity trial top-line data accelerated to late Q3 2025

Skye Bioscience, Inc.

Cash $68.4M at Dec 31, 2024; projected runway through at least Q1 2027.
Phase 2a CBeyond trial enrolled 136 patients; interim analysis removed; data expected late Q3/early Q4 2025.
Net loss FY2024 $26.6M vs $37.6M in 2023 (prior year included $21.2M IPR&D charge).
R&D expense FY2024 $18.7M (up from $5.8M) driven by Phase 2 trial and manufacturing costs.
Settled insurance litigation, received $2.0M cash proceeds in Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.